Can human genetics accelerate or improve the development phase
of the drug pipeline? When testing an antiobesity agent in terms of its
ability to reduce metabolic risk it might, for example, be possible to
enrich that group with genetic variants predisposing to type 2 diabetes
so that an impact of weight loss on adverse metabolic outcome might
be demonstrable earlier